Loading stock data…
ANRO
$21.15+2.91 (+15.95%)
After Hours$20.30-0.85 (-4.02%)· Last close Jun 9
Alto Neuroscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANRO in the Healthcare sector is trading at $21.15 with a market capitalization of $662M. Wall Street consensus targets $35.13 (11 analysts), implying a +66.1% move over the next 12 months. The stock is currently 26% below its 52-week high of $28.44, remaining 34.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +66.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$21.15
Potential Downside
0%
Whystock Fair Value$21.15
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$35.13+66.1%
Range$24.00 – $50.00
Fundamentals
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$661.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.53%
Volume
Today's trading volume
597,831
Recent News
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office market remains under pressure.
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
Alto Neuroscience deprioritized its lead asset Thursday, a treatment for cognitive impairment due to schizophrenia. The biotech stock tumbled.
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Thursday afternoon with the NYSE Health Care Index dropping 0.6% an
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
(Updates with the latest stock movement in the headline and the first paragraph.) Alto Neuroscien
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.